Clinical relevance of tumour-associated macrophages.
Mikaël J PittetOlivier MichielinDenis MiglioriniPublished in: Nature reviews. Clinical oncology (2022)
In the past decade, substantial advances have been made in understanding the biology of tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A particular aspect that is becoming increasingly clear is that the interaction of TAMs with cancer cells and stromal cells in the tumour microenvironment enables and sustains most of the hallmarks of cancer. Therefore, manipulation of TAMs could enable improved disease control in a substantial fraction of patients across a large number of cancer types. In this Review, we examine the diversity of TAMs in various cancer indications and how this heterogeneity is being revisited with the advent of single-cell technologies, and then explore the current knowledge on the functional roles of different TAM states and the prognostic and predictive value of TAM-related signatures. We also review agents targeting TAMs that are currently being or will soon be tested in clinical trials, and how manipulations of TAMs can improve existing anticancer treatments. Finally, we discuss how TAM-targeting approaches could be further integrated into routine clinical practice, considering a precision oncology approach and viewing TAMs as a dynamic population that can evolve under treatment pressure.
Keyphrases
- papillary thyroid
- single cell
- clinical practice
- clinical trial
- squamous cell
- end stage renal disease
- healthcare
- chronic kidney disease
- stem cells
- ejection fraction
- cancer therapy
- palliative care
- dna methylation
- gene expression
- drug delivery
- young adults
- childhood cancer
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- genome wide
- phase iii
- patient reported outcomes
- phase ii